Wiskott–Aldrich syndrome protein expression in female WAS carriers: A flow cytometry study from North India
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30972 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Suprit Basu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Immunology Unit, Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Wiskott-Aldrich Syndrome Protein, Wiskott-Aldrich Syndrome, Flow Cytometry, Heterozygote. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Introduction
Wiskott–Aldrich syndrome (WAS) is a rare X‐linked inborn error of immunity characterized by microthrombocytopenia, infections, eczema, and increased predisposition to develop autoimmunity and malignancy. Flow cytometric assay for determining WAS protein (WASp) is a rapid and cost‐effective tool for detecting patients. However, very few studies described WASp expression in female carriers. Most WAS carriers are clinically asymptomatic. Active screening of female family members helps identify female carriers, distinguish de novo mutations, and to select appropriate donor prior to curative stem cell transplantation. This study was undertaken to evaluate the diagnostic capability of flow cytometry‐based WASp expression in peripheral blood cells to identify carriers and compare WASp expression in different blood cell lineages. Patients and methods Female patients, heterozygous for WAS gene, were enrolled in this study conducted at Pediatric Allergy Immunology Unit, Advanced Pediatric Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Flow cytometric assessment of WASp expression in lymphocytes, monocytes, and neutrophils was carried out and compared with healthy control and affected patients. The results were expressed in delta (Δ) median fluorescence intensity (MFI) as well as stain index (SI), which is the ratio of ΔMFI of patient and ΔMFI of control.
Results
Thirteen mothers and two sisters of genetically confirmed WAS patients were enrolled in the study. All enrolled females were clinically asymptomatic and did not have microthrombocytopenia. Low WASp expression (SI < 1) was seen in lymphocytes and monocytes in 10 (66.6%) carriers. Females with variants in proximal exons (exons 1 and 2) were found to have lesser expression than those with distal (exons 3–12) variants.
Conclusion
Flow cytometry is a rapid, easily available, cost‐effective tool for WASp estimation. Lymphocytes followed by monocytes are the best cell lineages for WASp estimation in carrier females. However, genetic testing remains the gold standard, as carrier females with variants in distal exons may have normal WASp expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Immunology Unit, Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
ORCID-Profile: Suprit Basu, Amit Rawat
Förderung
- Indian Council of Medical Research
Zitieren
APA
Basu, S., Rikhi, R., Arora, K., Joshi, V., Sharma, S., Rawat, A., Singh, S., & Suri, D. (2024). Wiskott–Aldrich syndrome protein expression in female WAS carriers: A flow cytometry study from North India. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30972
Vancouver
Basu S, Rikhi R, Arora K, Joshi V, Sharma S, Rawat A, et al. Wiskott–Aldrich syndrome protein expression in female WAS carriers: A flow cytometry study from North India. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30972
BibTeX
@article{Basu2024,
author = {Basu, Suprit and Rikhi, Rashmi and Arora, Kanika and Joshi, Vibhu and Sharma, Saniya and Rawat, Amit and Singh, Surjit and Suri, Deepti},
title = {Wiskott–Aldrich syndrome protein expression in female WAS carriers: A flow cytometry study from North India},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30972}
}
EUVIMED